ACell, Inc., a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects, announced today that it has launched the roadshow for the initial public offering of its common stock. ACell is offering 5,000,000 shares of its common stock at an expected initial public offering price between $14.00 and $16.00 per share. ACell expects certain selling stockholders to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price, less underwriting discounts and commissions. ACell has applied to list its common stock on the Nasdaq Global Market under the ticker symbol "ACLL."
The offering is being made through an underwriting group led by UBS Investment Bank, Barclays and RBC Capital Markets who are acting as lead bookrunning managers, and SunTrust Robinson Humphrey who is acting as joint bookrunning manager.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (the "SEC") but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of shares of ACell's common stock in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About ACell, Inc.
ACell, Inc. is a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. ACell's products utilize its proprietary porcine urinary bladder matrix platform technology, which is designed to enhance the body's ability to restore natural tissue and minimize scarring in the management of traumatic, surgical and chronic wounds, burns, hernias and other conditions requiring the reinforcement of soft tissue.
